
Summit Therapeutics has revealed it is to terminate development of its Duchenne muscular dystrophy (DMD) drug ezutromid after it failed …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

